Gribero (Dabigatran Etexilate)

Gribero is indicated for several anticoagulant purposes in adult patients. It is prescribed to reduce the risk of thromboembolic events in specific clinical situations.

• Prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Treatment of acute deep vein thrombosis (DVT).
• Secondary prevention of recurrent DVT and pulmonary embolism (PE).
• Long‑term prevention of recurrent PE after an initial event.
• Post‑operative prophylaxis of venous thromboembolism in orthopedic surgery when approved.

Side effects of Gribero vary in frequency and severity. Common reactions are usually mild, while serious events are less frequent but require medical attention.

Common

• Minor gastrointestinal discomfort such as dyspepsia or nausea.
• Minor bleeding from gums or nose.
• Bruising at sites of minor trauma.
• Headache.
• Dizziness.

Serious

• Major bleeding, including intracranial hemorrhage.
• Gastrointestinal bleeding requiring hospitalization.
• Severe allergic reactions (anaphylaxis, angioedema).
• Liver enzyme elevations indicating hepatic injury.
• Thrombotic events despite therapy (rare).

Before initiating Gribero, clinicians should evaluate patient-specific factors and monitor for potential risks.

• Assess renal function; dose adjustment may be needed in impaired clearance.
• Avoid use in patients with active major bleeding or high bleeding risk.
• Use cautiously in the elderly and those with low body weight.
• Counsel patients on signs of bleeding and when to seek urgent care.
• Discontinue before elective surgery or invasive procedures as advised.
• Pregnancy and lactation status should be clarified; safety data are limited.

Gribero can interact with several medications that affect hemostasis or drug metabolism. Some combinations should be avoided, while others require careful monitoring.

Avoid

• Other anticoagulants (e.g., warfarin, heparin) and antiplatelet agents (e.g., clopidogrel, aspirin) unless specifically indicated.
• Strong P‑glycoprotein inhibitors (e.g., quinidine, itraconazole) that increase dabigatran exposure.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that raise bleeding risk.

Use with caution

• Moderate P‑glycoprotein inhibitors (e.g., amiodarone, verapamil).
• Renally cleared drugs that may accumulate in renal impairment.
• Herbal supplements such as ginkgo biloba or garlic that affect platelet function.